Manchester-based molecular diagnostics firm Yourgene Health plc announced on Wednesday a new collaboration between the recently launched Yourgene Genomic Services (YGS) and Cytox Ltd for a beta-testing genomic study on their genetic risk test for Alzheimer’s disease (AD).

Yourgene Health CEO Lyn Rees said: “This is an exciting partnership for Yourgene Genomic Services and a fine example of our ever-increasing product and service offering.

“We already have a well-established relationship with Cytox and are looking forward to working with them on this progressive technology.”

Cytox CEO Richard Pither said: “In Europe there are an estimated 1.6 million new cases of dementia each year, of which 800,000 are Alzheimer’s disease.

“As part of the disease management pathway, we anticipate clinicians adopting genoSCORE-LAB not only as an early test for patients concerned about future AD risk, but also to provide additional insight into potential disease progression in existing patients.

“We look forward to working with the Yourgene team on this initial Beta testing study ahead of our product launch.”